Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, capecitabine, irinotecan and bevacizumab for second-line treatment of unresectable cholangiocarcinoma
2013-001559-11Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Jun 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, capecitabine, irinotecan and bevacizumab in cholangiocarcinoma (CCA), sponsored by Herlev Hospital. Started Jun 2013; status: completed.
02
Drugs
gemcitabinecapecitabineirinotecanbevacizumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2013-001559-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001559-11.